Gillian A. Gray

Targeting C-reactive protein for the treatment of cardiovascular disease

Mark B. Pepys, Gideon M. Hirschfield, Glenys A. Tennent et al. · Nature · 2006 · 669 citations

Inflammation, Cardiovascular Disease, Medicine +5

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.

Martine Clozel, Volker Breu, Gillian A. Gray et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 667 citations

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist

Martine Clozel, Volker Breu, Kaspar F. Burri et al. · Nature · 1993 · 529 citations

Medicine, Vascular Pharmacology, Physiology +5

Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway

Géraldine Julou‐Schaeffer, Gillian A. Gray, Ingrid Fleming et al. · American Journal of Physiology-Heart and Circulatory Physiology · 1990 · 462 citations

Inflammation, Vascular Failure, Autoimmune Disease +14

The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo

Martine Clozel, Gillian A. Gray, Volker Breu et al. · Biochemical and Biophysical Research Communications · 1992 · 402 citations

Molecular Physiology, Medicine, Vascular Pharmacology +6